Fredric Price

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Selection of appropriate chemotherapy, including identification of platinum resistance, is critical to effective management of advanced epithelial ovarian cancer (EOC). ChemoFx®, a multiple treatment marker (chemoresponse assay), has been developed to address this challenge and to improve outcomes in patients with advanced EOC. While much work has been done(More)
  • 1